,58 Moreover, loss of 53BP1 has also been observed in patient-derived tumor xenograft (PDX) models with acquired resistance to PARPis, and mutations in TP53BP1 have been reported in tumor biopsies from patients with metastatic BRCA1-associated breast cancer receiving platinum chemotherapy or PARPis.27 This evidence concerns the gene BRCA1 and breast carcinoma.